Literature DB >> 24210071

Morphine improved the antitumor effects on MCF-7 cells in combination with 5-Fluorouracil.

Zhi-Hua Ge1, Zhi-Xue Wang1, Tie-Li Yu1, Ning Yang1, Yu Sun1, Chang-Lai Hao2, Li-Xin Sun3.   

Abstract

BACKGROUND: The most frequently used opioid in cancer pain management is morphine which remains a cornerstone for the management of cancer pain, due to the largest experience existing among physicians and widely availability in a variety of formulation. Considering that analgesics on cancer pain is often under the condition of chemotherapy and 5-Fluorouracil (5-FU) is widely used today as a potent drug for the treatment of advanced cancers, whether analgesics such as morphine, interferes the chemotherapy such as 5-FU, arose as a considerable problem.
METHODS: In this study, the MCF-7 breast cancer cells were used to determine the antitumor effects of the 5-FU in combination with morphine. The cell proliferation was determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and the apoptosis was determined by the Annexin V/PI staining and flow cytometry. The immunocytochemistry and western blot was used to determine the Bcl-2 and Bax expression.
RESULTS: It was shown that in MCF-7 cells, the proliferation was inhibited, the apoptosis was promoted, the Bcl-2 expression was suppressed and the Bax expression was promoted by both 5-FU alone and morphine alone, while the superior effects were achieved in combination with the two drugs.
CONCLUSION: These results suggest that the morphine may have the beneficial effects on the antitumor chemotherapy with 5-FU, in stead of interferential effects.
Copyright © 2013. Published by Elsevier Masson SAS.

Entities:  

Keywords:  5-Fluorouracil; Apoptosis; Bax; Bcl-2; Morphine; Tumor

Mesh:

Substances:

Year:  2013        PMID: 24210071     DOI: 10.1016/j.biopha.2013.09.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

Review 1.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

2.  Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts.

Authors:  Long-Hui Cao; Hui-Ting Li; Wen-Qian Lin; Hong-Ying Tan; Lan Xie; Zhong-Jian Zhong; Jian-Hua Zhou
Journal:  Sci Rep       Date:  2016-01-05       Impact factor: 4.379

3.  Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.

Authors:  Anna Lisa Iorio; Martina da Ros; Lorenzo Genitori; Maurizio Lucchesi; Fabiana Colelli; Giacomo Signorino; Francesco Cardile; Giacomo Laffi; Maurizio de Martino; Claudio Pisano; Iacopo Sardi
Journal:  Oncotarget       Date:  2017-08-03

4.  Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level.

Authors:  Yabing Ma; Zhongzhong Ren; Shuyong Ma; Wenjun Yan; Man He; Dong Wang; Peiyan Ding
Journal:  Ren Fail       Date:  2016-11-21       Impact factor: 2.606

Review 5.  The Potential Effect of Lidocaine, Ropivacaine, Levobupivacaine and Morphine on Breast Cancer Pre-Clinical Models: A Systematic Review.

Authors:  Ana Catarina Matos; Inês Alexandra Marques; Ana Salomé Pires; Ana Valentim; Ana Margarida Abrantes; Maria Filomena Botelho
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.